March 12, 2021 Amring Pharmaceuticals Inc. announced an agreement with Amzell B.V. for the commercial rights to a leading clinical-stage program that will bring critical and accessible therapy for patients in need. Read more
December 2, 2020 Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced the acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy...
March 1, 2017 Amring Pharmaceuticals Inc. acquired six ANDA’s from Luitpold Pharmaceuticals, Inc. and AlphaForce, L.L.P., a joint venture between Luitpold Pharmaceuticals, Inc. and Alphagen Laboratories Inc. The acquired ANDAs include niche otic and ophthalmic...
Recent Comments